Tatva Chintan Pharma Chem Q1 FY27 Results: Profit Jumps 140% as Revenue Hits Record High
By Kaushik Brahmakshatriya
Published On 20 July 2026.
Tatva Chintan Pharma Chem Q1 FY27 results
Tatva Chintan Pharma Chem Limited has delivered one of its strongest quarters on record, with the specialty chemicals maker posting a sharp jump in both profit and revenue for the quarter ended June 30, 2026. The Vadodara-headquartered company, known for manufacturing structure directing agents, phase transfer catalysts, and electrolyte salts used in lithium-ion batteries, announced these numbers after its board meeting held on July 17, 2026.
The consolidated net profit for Q1 FY27 came in at around Rs 16 crore, more than double the Rs 6.65 crore reported in the same quarter last year. This works out to a year-on-year growth of roughly 140 percent. On a sequential basis too, profit climbed nearly 55 percent compared with Rs 10.32 crore in the previous quarter, Q4 FY26
Revenue from operations also touched a record high of about Rs 167 crore, up close to 43 percent from Rs 117 crore in Q1 FY26 and up nearly 25 percent from Rs 134 crore in Q4 FY26. Analysts attribute this turnaround to stronger volume recovery, improving demand across the company’s product basket, and a stabilization in raw material costs after a prolonged period of pricing pressure in the specialty chemicals space.
Profitability metrics improved meaningfully as well. Operating profit, or EBITDA, rose to around Rs 32 crore from Rs 17 crore a year earlier, while the EBITDA margin expanded by more than 450 basis points to touch about 19.3 percent. Earnings per share for the quarter rose sharply to Rs 6.83, compared with Rs 2.84 in the year-ago quarter and Rs 4.41 in the preceding quarter.
Q1 FY27 Financial Highlights
| Metric | Q1 FY27 | Q1 FY26 | Q4 FY26 |
| Revenue | Q1 FY27 | Rs 117 crore | Rs 134 crore |
| Net Profit | Rs 16 crore | Rs 6.65 crore | Rs 10.32 crore |
| EBITDA | Rs 32 crore | Rs 17 crore | N/A |
| EBITDA Margin | ~19.3% | ~14.8% | N/A |
| EPS (Rs) | 6.83 | 2.84 | 4.41 |
Alongside the results, the board also cleared a major expansion plan. The company will set up a new greenfield manufacturing unit at Dahej-III in Bharuch district, Gujarat, adding 344 kilolitres of reactor capacity. The project carries an estimated investment of close to Rs 200 crore and is expected to be completed over roughly 21 months. To support this and other future capital needs, the board also raised the company’s borrowing limit from Rs 300 crore to Rs 1,000 crore, a move that will require shareholder approval before it takes effect. The board additionally cleared the re-appointment of three directors, signalling continuity in leadership through this growth phase.
Expansion & Capex Strategy
| Particular | Detail |
| New Facility Location | Dahej-III, Bharuch, Gujarat |
| Added Capacity | 344 KL reactor capacity |
| Estimated Investment | ~Rs 200 crore |
| Project Timeline | ~21 months |
| Revised Borrowing Limit | Rs 1,000 crore (from Rs 300 crore) |
Market watchers note that while the results mark a strong operational turnaround, the stock already trades at a rich valuation, with the trailing price-to-earnings ratio hovering near 79 times. The share price has gained more than 50 percent over the past year, comfortably outperforming broader specialty chemicals peers. Whether this premium is justified will likely hinge on the company executing its expansion plans on schedule and sustaining current margin levels in the quarters ahead.
Frequently Asked Questions FAQ
Q1. What is Tatva Chintan Pharma Chem’s net profit for Q1 FY27?
The company reported a consolidated net profit of around Rs 16 crore for the quarter ended June 30, 2026, up about 140 percent from the year-ago period.
Q2. How much revenue did Tatva Chintan Pharma Chem report in Q1 FY27?
Consolidated revenue stood at approximately Rs 167 crore, marking the company’s highest-ever quarterly revenue.
Q3. What was the EBITDA margin in Q1 FY27?
The EBITDA margin expanded to around 19.3 percent, up from about 14.8 percent in the same quarter last year.
Q4. What is the EPS for Q1 FY27?
Earnings per share came in at Rs 6.83 for the quarter, compared with Rs 2.84 a year earlier.
Q5. What expansion did the company announce along with its results?
The board approved a new greenfield unit at Dahej-III, Bharuch, Gujarat, with 344 KL of added capacity at an estimated cost of Rs 200 crore.
Q6. Did the board approve any change in borrowing limits?
Yes, the borrowing limit was raised from Rs 300 crore to Rs 1,000 crore, subject to shareholder approval.
Q7. What does Tatva Chintan Pharma Chem manufacture?
The company makes structure directing agents, phase transfer catalysts, electrolyte salts for lithium-ion batteries, and pharmaceutical and agrochemical intermediates.
Disclaimer: This article is for informational purposes only and should not be considered investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.We are not responsible for any loss.
